ZYME Stock Analysis: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$24.94
-0.94 (-3.63%)
▼
5d:
-1.54%
30d:
+9.15%
90d:
-5.24%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ZYME shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ZYME shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$0.32
Based on -37.9% avg growth
INTRINSIC VALUE TODAY
$0.20
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $24.94, which is considered fair relative to its 30-day fair value range of $23.02 to $25.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 87.8) compared to its historical average (60.8). At these levels, the market is pricing in 13.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ZYME is showing sideways momentum. Immediate support is located at $21.91, while resistance sits at $27.41. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: ZYME has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.33 (+57.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZYME is showing sideways momentum. Immediate support is located at $21.91, while resistance sits at $27.41. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: ZYME has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.33 (+57.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$23.02 -
$25.79
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.9%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 57.7% below Wall St target ($39.33)
- NEUTRAL: Trading at premium valuation - market expects 13.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$23.02 -
$25.79
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.45
(9.8%)
Support & Resistance Levels
Support Level
$21.91
Resistance Level
$27.41
Current Trend
Sideways
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
87.82
Wall Street Target
$39.33
(+57.7%)
Revenue Growth (YoY)
-91.1%
Profit Margin
-126.3%
Valuation Premium vs History
+13.1% premium
PE vs Historical
87.8 vs 60.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.1%
(market-implied from PE analysis)
1-Year Target
$28.21
(+13%)
2-Year Target
$31.90
(+28%)
3-Year Target
$36.08
(+45%)
3-Yr Target (if PE normalizes)
(PE: 88→61)
PE COMPRESSION
$24.98
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 87.8, Growth: -79.7%)
$18.18
(+-27%)
Base:
(SPY PE: 21.8, Growth: -79.7%)
$4.51
(-82%)
Bear:
(PE: 18.5, Growth: -79.7%)
$3.83
(-85%)
Share & Embed Analysis
Last updated: July 14, 2026 7:58 AM ET
Data refreshes hourly during market hours. Next update: 8:58 AM
Data refreshes hourly during market hours. Next update: 8:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
